MYD88 mutations can be used to identify malignant pleural effusions in Waldenstrom macroglobulinaemia
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status ...
What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study
Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia
